{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+as+placebo&page=2",
    "query": {
      "intervention": "Saline as placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 1082,
    "total_pages": 109,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+as+placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+as+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T06:17:10.627Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04370262",
      "title": "Multi-site Adaptive Trials for COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SOC + Intravenous Famotidine",
          "type": "DRUG"
        },
        {
          "name": "SOC + Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2020-04-07",
      "completion_date": "2020-09-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-11",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 5,
      "location_summary": "Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more",
      "locations": [
        {
          "city": "Bay Shore",
          "state": "New York"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "Mount Kisco",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Queens",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04370262"
    },
    {
      "nct_id": "NCT03991520",
      "title": "Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Endometriosis",
        "Anakinra",
        "Markers of Inflammation"
      ],
      "interventions": [
        {
          "name": "Anakinra 100Mg/0.67Ml Inj Syringe",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2020-06-16",
      "completion_date": "2022-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-28",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03991520"
    },
    {
      "nct_id": "NCT00882492",
      "title": "GLP 1 for Intraoperative Glycemic Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperglycemia",
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "GLP 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "normal saline solution placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2008-12",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2012-02-16",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00882492"
    },
    {
      "nct_id": "NCT03893565",
      "title": "Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "GSK2831781 - Double Blind Phase",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "GSK2831781 - Open Label phase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2019-05-06",
      "completion_date": "2021-05-17",
      "has_results": true,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 4,
      "location_summary": "Northridge, California • Rialto, California • New York, New York + 1 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893565"
    },
    {
      "nct_id": "NCT04620369",
      "title": "Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm",
        "Nasal Vestibulitis"
      ],
      "interventions": [
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Rose Geranium in Sesame Oil Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2020-11-13",
      "completion_date": "2022-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 20,
      "location_summary": "Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 16 more",
      "locations": [
        {
          "city": "Albert Lea",
          "state": "Minnesota"
        },
        {
          "city": "Brainerd",
          "state": "Minnesota"
        },
        {
          "city": "Deer River",
          "state": "Minnesota"
        },
        {
          "city": "Detroit Lakes",
          "state": "Minnesota"
        },
        {
          "city": "Duluth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04620369"
    },
    {
      "nct_id": "NCT02469857",
      "title": "Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Necrotizing Soft Tissue Infections",
        "Necrotizing Fasciitis",
        "Fournier's Gangrene"
      ],
      "interventions": [
        {
          "name": "AB103 0.5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "NaCl 0.9%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Atox Bio Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2015-12-01",
      "completion_date": "2019-10-18",
      "has_results": true,
      "last_update_posted_date": "2021-10-05",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02469857"
    },
    {
      "nct_id": "NCT03450707",
      "title": "Thiamine as a Metabolic Resuscitator After Cardiac Arrest",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiac Arrest"
      ],
      "interventions": [
        {
          "name": "Thiamine 500 mg IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Michael Donnino",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2018-05-06",
      "completion_date": "2022-02-19",
      "has_results": true,
      "last_update_posted_date": "2023-08-24",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03450707"
    },
    {
      "nct_id": "NCT06305793",
      "title": "RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "Long Coronavirus Disease 2019 (Covid19)",
        "Long Covid-19"
      ],
      "interventions": [
        {
          "name": "IVIG (intravenous immunoglobulin)",
          "type": "DRUG"
        },
        {
          "name": "IVIG Placebo",
          "type": "DRUG"
        },
        {
          "name": "Coordinated Care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Kanecia Obie Zimmerman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-05-08",
      "completion_date": "2026-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305793"
    },
    {
      "nct_id": "NCT03844061",
      "title": "Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo Subcutaneous Injection",
          "type": "OTHER"
        },
        {
          "name": "Placebo Infusion",
          "type": "OTHER"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-07-29",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03844061"
    },
    {
      "nct_id": "NCT00606905",
      "title": "Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Miscarriage, Recurrent",
        "Abortion, Habitual"
      ],
      "interventions": [
        {
          "name": "Gamimune N or Gamunex 10%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 82,
      "start_date": "1999-11",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2012-10-08",
      "last_synced_at": "2026-10-08T06:17:10.627Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00606905"
    }
  ]
}